Latest Bioxyne (Asx:Bxn) News

Page 2 of 2
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.
Victor Sage
Victor Sage
18 June 2025
Bioxyne Limited's subsidiary Breathe Life Sciences has achieved key GMP certifications across multiple international markets, paving the way for expanded operations in Europe, the UK, Canada, and Singapore. The company signals strong growth prospects for FY2026, with formal guidance expected in August.
Victor Sage
Victor Sage
18 June 2025
Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.
Victor Sage
Victor Sage
12 June 2025
Bioxyne Limited reports a remarkable 77% revenue increase in Q2 FY2025 alongside positive operating cash flow, setting the stage for international growth with imminent UK export approvals and planned European manufacturing.
Victor Sage
Victor Sage
28 Jan 2025
Bioxyne Limited reports a remarkable 77% revenue increase in Q2 FY2025 alongside positive operating cash flow, setting the stage for international growth with upcoming UK export approvals and a planned European GMP facility.
Victor Sage
Victor Sage
28 Jan 2025
Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.
Victor Sage
Victor Sage
23 Jan 2025